We are

De Motu Cordis

Our Mission

To deliver life-saving medicine faster when every second counts

OUR PURPOSE

We relentlessly seek new technologies that will save lives and improve outcomes for patients facing life-threatening emergencies

OUR STORY​

We’re an Australian clinical stage pharma company that pursues innovative product platforms for the emergency treatment of life-threatening conditions.

We were founded in Brisbane by ground breaking intensive care specialist and researcher, Professor John F Fraser. He understands the impact that anaphylaxis and cardiac arrest has on a patient’s outcomes and quality of life.

At DMC we see a critical need to deliver life-saving drugs faster to patients when they’re experiencing life-threatening situations outside of hospital. 

We are developing a needle-free device for people experiencing anaphylaxis.

We believe that faster epinephrine absorption via inhalation may prove to be a valuable alternative delivery mode not only for anaphylaxis but also for other emergency medical treatments.

Learn more about our people

Corporate Achievement

2019
  • Hire team
  • Appoint governing board
2020
  • Secured BDF funding and R&D Tax Incentives
  • Open new office premises
2021
  • Established QMS and cyber resilience
  • Seed capital, expanded facilities
  • Selected for BEDA Global Medtech Accelerator program
2023
  • Presented DMC progress at RESI conference, JP Morgan week, San Francisco

Product Development

2018
  • Texas Medical Centre Accelerator Program
2020
  • California Life Sciences Institute FAST Program, TIQ sponsorship
  • Successful API particle engineering
  • US Patent granted
2021
  • Formulation developed for rapid Tmax via the lung
  • GMP manufacture for Phase 1
2022
  • Completion of testing for non-clinical program
  • Successful first human clinical study
  • Completion of Institutional Review Board (IRB) approved quantitative market research
  • EU patent granted
2022
  • Pre-IND/FDA engagement
  • US based commercial CDMO onboarded
  • DMC-IH1 in vitro DPI device performance exceeds industry benchmark
  • Completed formative Human Factors (HF) study